## **CLAIMS**

## What is Claimed:

- 1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
  - (d) sequences set forth in SEQ ID NO:594-627;
- (e) sequences having at least 70% identity to a sequence set forth in SEQ ID NO:594-627; and
- (f) sequences having at least 90% identity to a sequence set forth in SEQ ID NO:594-627.
- 2. An expression vector comprising a polynucleotide encoding a polypeptide of claim 1 operably linked to an expression control sequence.
- 3. A host cell transformed or transfected with an expression vector according to claim 2.
- 4. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide of claim 1.
- 5. A method for detecting the presence of a cancer in a patient, comprising the steps of:
  - (a) obtaining a biological sample from the patient;
- (b) contacting the biological sample with a binding agent that binds to a polypeptide of claim 1;
- (c) detecting in the sample an amount of polypeptide that binds to the binding agent; and

- (d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient.
- 6. A fusion protein comprising at least one polypeptide according to claim 1.
- 7. A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of:
  - (a) polypeptides according to claim 1;
  - (b) polynucleotides encoding a polypeptide according to claim 1;
  - (c) antibodies according to claim 4;
  - (d) fusion proteins according to claim 6;
- (e) antigen presenting cells that express a polypeptide according to claim 1.
- 8. A method for stimulating an immune response in a patient, comprising administering to the patient a composition of claim 7.
- 9. A method for the treatment of a cancer in a patient, comprising administering to the patient a composition of claim 7.
- 10. A diagnostic kit comprising at least one antibody according to claim 4 and a detection reagent, wherein the detection reagent comprises a reporter group.